<p>This is a summary of the European public assessment report (EPAR) for Cayston. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Cayston.</p>
Therapeutic Indication
<div class="subsection mt-3-5"> <h3>Therapeutic indication</h3><p>Cayston is indicated for the suppressive therapy of chronic pulmonary infections due to <em>Pseudomonas aeruginosa</em> in patients with cystic fibrosis (CF) aged 6 years and older.</p> <p>Consideration should be given to official guidance on the appropriate use of antibacterial agents.</p></div>
Therapeutic Area (MeSH)
ATC Code
J01DF01
ATC Item
N/A
Pharmacotherapeutic Group
Antibacterials for systemic use
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| aztreonam lysine | N/A | aztreonam lysine |
EMA Name
Cayston
Medicine Name
Cayston
Aliases
N/ANo risk management plan link.
